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       Atherosclerosis is a complex inflammatory disease and it represents a major source of 
morbidity and mortality in the world as a part of cardiovascular diseases. Endothelial 
dysfunction represents the first step in the development of atherosclerosis and it is characterized 
by disruption of endothelial homeostasis. Statins are drugs of choice in the treatment of 
atherosclerosis and they can decrease LDL cholesterol levels and positively affect levels of 
HDL cholesterol. Statins, however have a wide range of other effects, which are referred to 
non-lipid or pleotropic effects. The most important non-lipid effects of statins are lipid-
independent modulation of endothelial function, antioxidant, anti-inflammatory, 
antithrombogenic and antiproliferative effects.  
 The most widely used animal model for the study of atherosclerosis is the mouse model. 
Thanks to a high fat diet and genetic modification, we are able to modify lipid profile in mice 
and induce atherosclerotic changes even at early age of mice. During the process of 
atherogenesis in the arteries, pathological changes occur on the immunological, morphological 
and functional levels. Signaling pathway of transforming grow factor beta (TGF-β) plays an 
important role during these processes.  
 The publications presented in this thesis mainly focus on the role of endoglin (auxiliary 
TGF-β receptor III) and its soluble form in endothelial dysfunction in selected mouse models. 
Changes of endoglin expression and increased levels of soluble endoglin were demonstrated in 
many cardiovascular diseases including atherosclerosis, hypertension, type II diabetes mellitus 
and preeclampsia.  
 We have demonstrated that endoglin is not expressed with adhesion molecules  
(ICAM-1, P-selectin) in aortic endothelium of atherosclerotic plaques in apoE deficient mice 
during atherogenesis and thus endoglin is probably not involved in the accumulation and 
transmigration of leukocytes during atherogenesis.  
 We could not demonstrate endothelial dysfunction in the aorta of mice with high levels 
of human soluble endoglin (Sol-Eng+) in plasma on chow diet. Administration of high fat diet 
to these mice resulted in activation of pro-inflammatory markers (ICAM-1, P-selectin, COX-1 
and pNFκB) and induced oxidative stress (NOX-1, NOX-2 and HO-1) in aorta. The 
endothelium-dependent vasodilatation of aorta was more impaired in the group with low levels 
of soluble endoglin in plasma and preserved in group with high levels of soluble endoglin in 
plasma. These results suggest that high concentrations of soluble endoglin in plasma induce the 
activation of pro-inflammatory, pro-oxidative as well as vasoprotective mechanisms in the 
vessel wall. The role of soluble endoglin in endothelial dysfunction and its relationship with 
hypercholesterolemia were discussed in our review article. We have demonstrated a positive 
correlation of soluble endoglin and hypercholesterolemia in C57BL/6J mice, apoE deficient 
mice on chow diet, apoE deficient and apoE/LDLR deficient mice on cholesterol diet. The 
highest levels of soluble endoglin were observed in apoE/LDLR deficient mice fed cholesterol 
diet – the group with the highest progression of atherosclerosis. In this study, we also 
summarized current knowledge of soluble endoglin and its relation to endothelial dysfunction 
and atherogenesis. We suggest that soluble endoglin represents an interesting biomarker of 
progression and treatment of many cardiovascular diseases associated with endothelial 
dysfunction.      
